Background PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line
treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there …

… This trial was designed as a multicentre, prospective, randomised phase III trial. The study …
our previous phase II trial for elderly patients with extensive disease small-cell lung cancer (ED…

PURPOSE The CHOICE-01 study investigated the efficacy and safety of toripalimab in
combination with chemotherapy as a first-line treatment for advanced non–small-cell lung cancer (…

… The primary endpoint was objective tumor response rate. This study employed a “pick up
the winner” design based on the randomized phase II clinical trial approach proposed by …

Background Concurrent chemotherapy and thoracic radiotherapy followed by prophylactic
cranial irradiation (PCI) is the standard treatment in limited-disease small-cell lung cancer (LD…

… For three decades now, cisplatin has been a basic cytotoxic agent used for the treatment of
stage III and IV non-small-cell lung cancer (NSCLC). Cisplatin-based doublet chemotherapy …

Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated patients
with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor receptor …

… with stage IIIB/IV non-small-cell lung cancer or postoperative recurrence harbouring EGFR
mutations (either the exon 19 deletion or L858R point mutation) were randomly assigned, …

… Tumor angiogenesis is an important factor affecting tumor growth [5]. Almost 80% of
small cell lung cancer tissues have VEGF expression, and anti-angiogenesis studies on ED-SCLC …

… -small-cell lung cancer (NSCLC) and disease progression after platinum-based chemotherapy.
We searched PubMed with the terms (“non-small cell lung cancer… were randomised trials …